Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
A randomized phase II-study to evaluate the safety and efficacy of capecitabine plus
irinotecan plus cetuximab compared to capecitabine plus oxaliplatin plus cetuximab in
first-line treatment of patients with metastatic colorectal cancer.